Global Mydriasis Treatment Market - 2023-2030

Overview

Mydriasis is also known as dilated pupils. Mydriasis occurs when the black center of the eyes is larger than normal. The condition may be caused by dilating eye drops from an eye exam, the side effects from any drugs or medication or traumatic injury. Pupils naturally dilate due to changes in light and emotional events, but unusual pupil dilation could be the result of a medical condition. A pupil's normal size is 2 to 4 millimeters in bright light and 4 to 8 millimeters in dim light (dilated).

Moreover, most of the time, dilated pupils will back to normal size on their own. If pupils dilate suddenly, occur after a traumatic injury or cause headaches and confusion, need to seek medical attention immediately. The treatment of mydriasis includes wearing sunglasses to reduce sunlight sensitivity, especially photochromic lenses and polarized lenses are commonly used, wearing prosthetic contact lenses to improve the appearance of eyes as the result of varying pupil size caused by trauma, substance abuse rehabilitation and in some situations surgery is considered to repair eye damage from injury.

Market Dynamics: Drivers

Increasing adoption of ophthalmic solutions

The increasing adoption of ophthalmic solutions is expected to drive the market over the forecast period. Ophthalmic solutions, such as eye drops are often mostly preferred by mydriasis patients due to their non-invasive nature. This preference increases patient compliance with the prescribed treatments, leading to better outcomes. Due to the increasing adoption, many companies are focussing on developing ophthalmic solutions.

For instance, on September 27, 2023, Viatris Inc. released that the U.S. Food and Drug Administration (FDA) approved RYZUMVI (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.

Moreover, many clinical trials are going on for the development of novel ophthalmic solutions that show better results in mydriasis treatment. Public awareness campaigns and educational initiatives about the importance of regular eye examinations and early intervention for eye conditions are contributing to a more proactive approach to eye care. This, in turn, drives the adoption of ophthalmic solutions mostly in the treatment of mydriasis.

Further, many regulatory approvals such as FDA approvals for novel ophthalmic solutions increase the trust in patients for the usage of ophthalmic solutions. For instance, on February 13, 2023, Ocuphire Pharma, Inc. cleared the U.S. Food and Drug Administration (FDA) acceptance for the New Drug Application (NDA) for Nyxol (phentolamine ophthalmic solution 0.75%) for the treatment of pharmacologically-induced mydriasis.

Further, the increasing prevalence of mydriasis, rising regulatory approvals for novel therapeutics, increasing clinical trials and research activities, increasing awareness about mydriasis, mydriatic lenses and their treatment and technological advancements in developing novel treatments are expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with the surgery, side effects associated with the eye drops, the discomfort of the contact lenses, the high cost of the treatment of mydriasis and lack of better and quick treatment are expected to hamper the market.

Segment Analysis

The global mydriasis treatment market is segmented based on treatment type, sales channel and region.

The sunglasses segment accounted for approximately 42.2% of the mydriasis treatment market share

The sunglasses segment is expected to hold the largest market share over the forecast period. Sunglasses with photochromic lenses and polarized lenses are most commonly used to reduce sunlight sensitivity. Sometimes, individuals with mydriasis experience increased sensitivity to light, in such situations, sunglasses can help manage this sensitivity of the light by reducing the amount of light entering the eyes.

In addition, after certain eye surgeries or other mydriatic medical procedures, patients may be advised to wear sunglasses to protect the eyes from bright light and it reduces discomfort. While mydriatic sunglasses do not directly treat mydriasis, they can provide symptomatic relief by minimizing discomfort caused by bright light, glare, or intense sunlight.

Further, the wide availability and acceptability of the mydriatic sunglasses helps to hold the largest market share. In addition, their wide adoption also increases the demand for the sunglasses.

Geographical Analysis

North America accounted for approximately 39.2% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing research activities. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies and medical device companies for developing novel ophthalmic solutions and advanced eyewear such as sunglasses and contact lenses. The presence of major players actively performing in clinical trials, leads to the launch of novel therapeutics and alternative treatment options for the treatment of mydriasis.

Furthermore, the increasing research activities especially in the United States also helps to develop more advanced therapeutics for the better management of the symptoms in the early stages. As the research activities increase, the therapeutics are developed more precisely by reducing the adverse effects and complications associated with the therapeutics and devices, which results in better patient outcomes.

Competitive Landscape

The major global players in the mydriasis treatment market include: Omeros Corporation, Thea Laboratories, Ocuphire Pharma, Inc., Alcon Inc., Hoya Vision, Maui Jim USA, Inc., Safilo Group S.p.A., Global Calcium Pvt Ltd, VISION EASE, ZEISS Group and among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global mydriasis treatment market. The pandemic created unprecedented challenges for pharmaceutical industries worldwide. During the pandemic, many clinical trials, research activities and regulatory approvals are temporarily disrupted or postponed due to the redirected focus on the COVID-19 pandemic and its related restrictions. The pandemic also disrupted the supply chain of these treatment medications and eyewear globally.

Market Segmentation

By Treatment Type

• Sunglasses
  • Photochromic Lenses
  • Polarized Lenses
  • Others
• Prosthetic Contact Lenses
• Surgery
• Substance Abuse Rehabilitation
• Eye Drops
  • Atropine
  • Mydrilate
  • Homatropine
  • Phenylephrine
  • Others
• Others

By Sales Channel

• Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• End-User
  • Hospitals
  • Ophthalmic Clinics
  • Rehabilitation Centers
  • Ambulatory Surgical Centers
  • Academic and Research Institutes
  • Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Why Purchase the Report?

• To visualize the global mydriasis treatment market segmentation based on treatment type, sales channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of mydriasis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global mydriasis treatment market report would provide approximately 53 tables, 49 figures, and 187 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies